Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Orforglipron in Chinese Adults With Obesity or Overweight
NCT07790861Phase 3
Key facts
- Status
- Not yet recruiting
- Start
- Dec 2026
- Primary completion
- Mar 2028
- Countries
- 1
- Sponsor
- Eli Lilly and Company
- Drugs
- orforglipron
- Conditions
- obesity
01
Overview
Phase 3, randomised, double-blind trial in obesity comparing Orforglipron with Placebo (2 arms). Primary endpoint: Mean Percent Change From Baseline in Body Weight at 48 weeks. Planned start Dec 2026; status: not yet recruiting.
02
Design
2 arms- Study design
- RandomizedDouble-blind
Orforglipron
Participants will receive orforglipron orally.
Placebo
Participants will receive placebo orally.
03
Who it enrols
Chinese adults with obesity or overweight (BMI >= 24.0) and at least one weight-related comorbidity, with a history of unsuccessful dietary effort to lose weight. Excludes patients with any type of diabetes, recent significant weight change, history of pancreatitis, or personal/family history of medullary thyroid carcinoma or MEN2 syndrome.
04
Endpoints
Primary
Mean Percent Change From Baseline in Body Weight
Secondary
Mean Change from Baseline in Waist Circumference
Mean Change from Baseline in Body Mass Index
Mean Change from Baseline in Hemoglobin A1c
Mean Change from Baseline in Fasting Glucose
Mean Percent Change from Baseline in Fasting Insulin
Mean Change from Baseline in Systolic Blood Pressure
Mean Change from Baseline in Diastolic Blood Pressure
Mean Percent Change from Baseline in Fasting non-HDL Cholesterol
Beyond the preview
Go deeper on NCT07790861.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07790861.